128 related articles for article (PubMed ID: 25016812)
1. [Molecular target therapy for non-Hodgkin lymphoma].
Kato H; Kinoshita T
Nihon Rinsho; 2014 Jun; 72(6):1104-12. PubMed ID: 25016812
[TBL] [Abstract][Full Text] [Related]
2. Innovative strategies in lymphoma therapy.
Jäger U
Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264
[TBL] [Abstract][Full Text] [Related]
3. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
4. Hematologic malignancies: new developments and future treatments.
Cheson BD
Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
[TBL] [Abstract][Full Text] [Related]
5. New agents for the treatment of lymphoma.
Stathis A; Ghielmini M
Ann Oncol; 2012 Sep; 23 Suppl 10():x92-8. PubMed ID: 22988000
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Zinzani PL; Pellegrini C; Merla E; Ballerini F; Fabbri A; Guarini A; Pavone V; Quintini G; Puccini B; Vigliotti ML; Stefoni V; Derenzini E; Broccoli A; Gandolfi L; Quirini F; Casadei B; Argnani L; Baccarani M
Hematol Oncol; 2013 Dec; 31(4):179-82. PubMed ID: 23108928
[TBL] [Abstract][Full Text] [Related]
7. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
8. ["Magic bullets"--monoclonal antibodies in acute leukemia and non-Hodgkin's lymphoma treatment].
Łuczyński W; Krawczuk-Rybak M
Postepy Hig Med Dosw; 2002; 56(6):789-801. PubMed ID: 12669700
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Smith MR; Jin F; Joshi I
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
[TBL] [Abstract][Full Text] [Related]
11. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
Delmonte A; Ghielmini M; Sessa C
Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316
[TBL] [Abstract][Full Text] [Related]
12. Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
Rummel M
J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 6():S1-14; quiz S15. PubMed ID: 20876549
[TBL] [Abstract][Full Text] [Related]
13. [Molecular target drugs of a malignant lymphoma and lymphoid leukemia].
Kamata H; Kimura H; Higashihara M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():513-7. PubMed ID: 23513893
[No Abstract] [Full Text] [Related]
14. The spectrum of kidney involvement in lymphoma: a case report and review of the literature.
Cohen LJ; Rennke HG; Laubach JP; Humphreys BD
Am J Kidney Dis; 2010 Dec; 56(6):1191-6. PubMed ID: 20843590
[TBL] [Abstract][Full Text] [Related]
15. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.
Yan M; Dong Z; Zhao F; Chauncey T; Deauna-Limayo D; Wang-Rodriguez J; Liu D; Wang HY; Pilz R
Eur J Haematol; 2014 Jul; 93(1):77-80. PubMed ID: 24528507
[TBL] [Abstract][Full Text] [Related]
16. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
17. Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
Kahl BS; Cheson BD; Friedberg JW
Clin Adv Hematol Oncol; 2010 May; 8(5):1-16. PubMed ID: 20712081
[TBL] [Abstract][Full Text] [Related]
18. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
19. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
20. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
